| Study Title | AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
|---|---|
| Protocol ID | AALL1631 |
| Disease (Sub Disease) | Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia |
| Diagnosis Stage | New diagnosis |
| Location | NSW / QLD / WA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI)/ EsPhALL network I-BFM Study Group |
| Links | https://clinicaltrials.gov/ct2/show/NCT03007147 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 19/04/2018 |
| Trial Close Date | 01/10/2024 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Christchurch Hospital, NZ/ Starship Hospital, NZ/ John Hunter Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 1 year to 21 years at diagnosis |
| International registry ID's | NCT03007147 |